News

NSF Awards NOVA’s Biotechnology Program $550,000 for NOBLE Project

The NOVA Biotechnology and Leadership in Education (NOBLE) Project will be funded by the National Science Foundation with more than $550,000 over the next three years. The goal of the NOBLE Project is to revitalize and grow the biotechnology program. The NOBLE Project seeks to recruit students throughout the entire NOVA service area, particularly minorities in STEM, veterans and dual-enrollment students. The NOBLE Project will include faculty from the Alexandria and Manassas campuses.

The goal of the NOBLE Project is to train students in technical and professional skills to increase their competitiveness in the biotechnology job market. Students will gain additional key experiences by attending scientific conferences and connecting with scientific organizations. Importantly, the grant will provide funds for paid internships at local biotechnology companies. Work will begin this summer. Interested students should contact Xin Zhou at xzhou@nvcc.edu or David Fernandez at dfernandez@nvcc.edu.

The principle investigator (PI) of this project, Dr. David Fernandez, thanks Dr. Eun-Woo Chang, vice president of academic affairs and chief academic office; Dr. Xin Zhou, NOVA biotechnology program head; Dr. Maggie Emblom-Callahan, interim dean of MSTB Alexandria and Dr. Diane Mucci, Annandale Campus provost, for their guidance and vision in crafting this project.

Recent News

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza